Related Experiment Video
Updated: Feb 26, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
As-Needed Medication Use for Agitation Across Valproic Acid Formulations
Michael Ley1,2, Casey Tiefenthaler1, Jamie Kneebusch3
1Department of Pharmacy, UC San Diego Health, San Diego, California.
Background:
Pharmacokinetic differences between immediate-, delayed- and extended-release (IR, DR, ER) formulations of valproic acid (VPA) may impact therapeutic outcomes. As-needed, pro re nata (PRN) medications may serve as proxies for scheduled medication effectiveness for symptom management. This study compared the number of PRN doses of benzodiazepines and antipsychotics for agitation between VPA formulations.
Methods:
A retrospective review was conducted for patients with bipolar I or schizoaffective disorder who received three or more days of VPA (IR, DR, ER) doses as maintenance therapy. The primary outcome was the difference in average daily number of PRN benzodiazepine and/or antipsychotic doses for agitation across formulations. The secondary outcome included differences in VPA total daily dose (TDD) across formulations. Descriptive statistics, ANOVA, and hierarchical multiple regression analyses were used for comparisons.
Results:
A total of 150 patients were included (59% male, 55% Caucasian). The VPA formulation was significantly associated with the average daily PRN antipsychotic and/or benzodiazepine doses, as well as antipsychotic alone, after adjusting for potential confounders (age, sex, race, psychiatry unit, average VPA total daily dose).
Conclusion:
The significant difference in the number of PRN benzodiazepine and/or antipsychotic doses administered for agitation among the different formulations of VPA may suggest differences in symptom control. Further investigation is warranted.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Dosage Regimen: Individualization
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimens: Partial Pharmacokinetic Parameters

